ALSO NOTED: BioMarin offers $250M in notes; NeurogesX amends IPO terms; and much more...

> BioMarin is making an offering of $250 million in senior notes. Report

> NeurogesX has amended its IPO terms and now plans to sell 4 million shares at $13 to $15 a share. Report

> The FDA has approved a new dose of Sanofi's osteoporosis drug Actonel. Report

> Salix Pharmaceuticals will gain up to $4 million in milestones and royalties from Dr. Falk Pharma in exchange for the licensing rights to DIACOL for 28 territories in Europe. Report

> SCOLR Pharma announced positive new data for its extended release ibuprofen OTC product candidate. Release

> GE Healthcare has acquired Wave Biotech, which sells disposable manufacturing technology to the biopharma industry. Report

> Researchers at the University of Bristol say that they've found a protein--JAM-1--in the walls of the blood vessels in the brain that may be directly linked to high blood pressure. Report

> A group of academic research centers has reorganized around the NIH's $100 million program to encourage translational research, bringing scientists and clinicians together to advance therapies in clinical trials. Report

> Scientists at Oxford and the University of Exeter say that a variant of the FTO gene that is carried by 16 percent of white Europeans made them 70 percent more likely to be obese than those with an alternative variant. Report

And Finally… A new study says that the massive growth of the Gates Foundation will create a significant competitor with government-funded and commercial drug developers for new drug research. Article

Suggested Articles

J&J's EGFR-fighting combo stopped tumor growth in 60% of patients whose lung cancer got worse after taking AstraZeneca's Tagrisso.

Amgen's KRAS inhibitor curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of them.

The trial squeezed under the bar for statistical significance by improving on the median progression-free survival of Zytiga by two months.